Curcumin in Cell Death Processes: A Challenge for CAM of Age-Related Pathologies by Salvioli, S. et al.
Advance Access Publication 23 April 2007 eCAM 2007;4(2)181–190
doi:10.1093/ecam/nem043
Review Article
Curcumin in Cell Death Processes: A Challenge for CAM of
Age-Related Pathologies
S. Salvioli
1,2, E. Sikora
3, E. L. Cooper
4 and C. Franceschi
1,2,5
1Department of Experimental Pathology and Centro Interdipartimentale ‘‘L. Galvani’’, University of Bologna,
via S. Giacomo 12, 40126 Bologna, Italy,
2ER-GenTech laboratory, via Saragat 1, 44100 Ferrara, Italy,
3Department of Cellular Biochemistry, Nencki Institute of Experimental Biology, 3 Pasteura St., 02-093 Warsaw,
Poland,
4Laboratory of Comparative Neuroimmunology, Department of Neurobiology, David Geffen School
of Medicine at UCLA, University of California at Los Angeles, Los Angeles California 90095-1763 and
5I.N.R.C.A., Department of Gerontological Sciences, via Birarelli 8, 60121 Ancona, Italy
Curcumin, the yellow pigment from the rhizoma of Curcuma longa, is a widely studied phyto-
chemical which has a variety of biological activities: anti-inflammatory and anti-oxidative.
In this review we discuss the biological mechanisms and possible clinical effects of curcumin
treatment on cancer therapy, and neurodegenerative diseases such as Alzheimer’s Disease, with
particular attention to the cell death processes induced by curcumin. Since oxidative stress
and inflammation are major determinants of the aging process, we also argue that curcumin can
have a more general effect that slows down the rate of aging. Finally, the effects of curcumin
can be described as xenohormetic, since it activates a sort of stress response in mammalian cells.
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Introduction: A Natural Treatment for Cancer
and Other Age-related Diseases
Curative Properties Against Cancer
For many centuries, turmeric has been used throughout
Asia as a food additive and a traditional herbal medicine
as well. Curcumin (diferuloylmethane), the yellow pigment
extracted from the rhizoma of Curcuma longa, is the
pharmacologically active substance of turmeric. Curcumin
is nontoxic and has a variety of positive pharmacological
effects: indeed, anti-oxidative, anti-inflammatory and anti-
septic properties have been reported (1–3). Curcumin also
has several of biological activities that eventually render
this molecule a possible anti-cancer drug, as both chemo-
preventive and chemotherapeutic. Indeed, many lines
of evidence indicate that curcumin contributes to the
inhibition of tumor formation, promotion, progression
and dissemination in many animal models (4). In partic-
ular, curcumin can inhibit both tumor initiation induced
by benzo[a]pyrene and 7,12 dimethylbenz[a]anthracene
(5) and tumor promotion by phorbol esters (6,7). Dietary
administration of curcumin significantly inhibits skin, oral,
forestomach, duodenal, colon and tongue carcinogenesis
in mice and rats (8–11). As a whole, this body of evidence
has strongly suggested that curcumin can be considered
a promising tool for cancer therapy and, in recent years,
a number of Phase I human trials have been performed,
showing this compound to be well-tolerated (12–15).
Overall, these studies confirmed the lack of toxicity of
curcumin administration and also suggested a biologic
effect of curcumin in the chemoprevention of cancer.
Other Known Treatments
Beside cancer, curcumin is considered a promising drug
for the treatment of other diseases, most of which are
For reprints and all correspondence: Prof. Claudio Franceschi,
Department of Experimental Pathology and Centro Interdipartimentale
‘‘L. Galvani’’, University of Bologna, via S. Giacomo 12, 40126
Bologna, Italy. E-mail: claudio.franceschi@unibo.it
 2007 The Author(s)
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/
licenses/by-nc/2.0/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original worki s
properly cited.related to the aging process. Indeed curcumin has an
anti-oxidant and anti-inflammatory activity, as men-
tioned above, so it could likely ameliorate a series of
pathogenetic conditions that share an inflammatory or
oxidative basis, such as cardiovascular diseases, sporadic
Alzheimer’s disease (AD), sarcopenia, type II diabetes,
arthrosis and arthritis among others (16–21). In recent
years, curcumin is also proposed as a possible tool to
cure, or at least ameliorate, cystic fibrosis (22,23).
Inflamm-aging
We recently suggested that successful aging derives from
the capability to cope with inflammatory responses
evoked by long-lasting stressors (24). Such stressors can
induce a chronic pro-inflammatory status characteristic
of aging that we have proposed to call ‘inflamm-aging’
(25). Stressor agents can include physiochemical and
biotic agents like viral and bacterial antigens, UV rays,
environmental chemicals and so on. The response to such
agents is mostly of inflammatory type, and consequently,
a chronic exposure to these agents induces an increase in
inflammatory markers in the elderly. If anti-inflammatory
mechanisms fail to counteract such responses, inflamma-
tion-based diseases eventually occur. In this perspective,
drugs that can change the balancing between inflamma-
tion and anti-inflammation toward anti-inflammation
can, at least in theory, help in avoiding, delaying or
diminishing inflammation-based diseases.
Oxidative Stress
Oxidative stress, and the consequent accumulation of
molecules damaged by oxidant by-products of respiratory
metabolism, is considered a major cause of aging (26).
Most agents that activate a major transcription factor,
such as NF-kB, are either modulated by oxidative stress
or are pro-oxidants themselves (27) or are oxidized
molecules, such as Large Density Lipoproteins (28).
Many genes coding for pro-inflammatory cytokines are
mainly transcripted upon NF-kB activation, thus oxida-
tive stress (mostly due to mitochondrial metabolism) can
impinge upon the aging process through inflammatory
reactions, and pro-inflammatory cytokines can be the
link between aging and oxidative stress (29). One of the
most important cellular defense mechanisms against
oxidative stress or electrophiles is mediated by the
transcription factor Nrf2 (30). Once activated, Nrf2 is
able to activate the antioxidant-responsive element
(ARE)-dependent gene expression in order to maintain
cellular redox homeostasis. Curcumin can stimulate the
expression of Nrf2 in a concentration- and time-
dependent manner (31). Thus, curcumin can counteract
the effect of oxidative stress through this pathway and
help in avoiding, delaying or slowing down aging as well
as age-related diseases that share an oxidative damage,
such as the complications of type II diabetes (32).
Taking into consideration that curcumin is provided
with anti-proliferative and pro-apoptotic activities, as
well as anti-oxidant and anti-inflammatory capabilities,
it is reasonable to propose that curcumin (and likely
other phytochemicals) should be considered a possible
tool to complement pharmacological therapies not only
for cancer but also for many other age-related diseases,
including neurodegeneration and chronic inflammation.
We will briefly summarize the effects of curcumin by
focusing in particular on cell death, and the consequences
of such effects on neurodegeneration and aging. Finally,
we will speculate on curcumin’s action as a possible
example of xenohormesis.
Curcumin and Cell Death
Molecular Targets
According to one hypothesis, the anti-cancer activity of
curcumin may originate, at least in part, from its capability
to induce antioxidant and phase II metabolizing enzymes
involved in detoxification, as observed in ddY male mice
(33). Nevertheless, several different curcumin activities
with potential anticancer effects have been reported
(4,34,35). Evidently from the review of Aggarwal et al.
(34) curcumin suppresses proliferation of a wide variety of
tumor cells, down-regulates transcription factors such as
NF-kB, AP-1 and Egr-1; down-regulates the expression of
Cyclooxygenase-2, Lipooxygenase, Nitric Oxide Synthase,
Matrix metalloproteinase 9, urokinase-type Plasminogen
Activator, tumor necrosis factor (TNF), chemokines, cell
surface adhesion molecules and cyclin D1; down-regulates
growth factor receptors (such as EGFR and HER2); and
inhibits the activity of c-Jun N-terminal kinase, protein
tyrosine kinases and protein serine/threonine kinases.
Furthermore, curcumin has an anti-angiogenic activity
(3) and it can induce cell death in a wide variety of in vitro
cancer and noncancer cell cultures. A number of excellent
reviews do already exist on this topic (4,34–36). We will
focus on the capability of curcumin to induce different
processes of cell death by analyzing the underlying
molecular mechanisms. We will also consider the biphasic
behavior of curcumin, and the possibility that curcumin
cannot only induce but also protect against cell death.
In in vitro studies, curcumin inhibits proliferation
and/or induces cell death in many different cell types.
The most common cell death process induced upon
curcumin treatment seems to be apoptosis, even if other
processes (necrosis, mitotic catastrophe, see subsequent
text) cannot be excluded. Accordingly, curcumin is
known to induce apoptosis in numerous animal
and human cell lines, like leukemia, melanoma, breast,
lung, prostate, colon, renal, hepatocellular and ovarian
carcinomas [reviewed in (37) and (38)].
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Curcumin can induce the mitochondrial-dependent apo-
ptotic pathway, as the release of cytochrome c and other
proapoptogenic mitochondrial factors such as AIF have
been shown in different human cells upon curcumin
treatment (38,39), although a Fas/caspase-8 pathway has
also been observed (40). Curcumin-induced apoptosis
has been reported to be p53-dependent (41,42). However,
we have observed that apoptotic phenomena also occur
in p53-deficient HL-60 cells upon curcumin treatment
(43,44), and other authors also showed that the
curcumin-induced apoptosis of lung and colon cancer
cells appears to be p53-independent (45). Similarly, the
role of Bcl-2 family proteins in the curcumin-induced
apoptosis remains elusive (45–47). Moreover the role
of reactive oxygen species (ROS) in curcumin-induced
apoptosis is controversial, since curcumin can exert both
pro- and anti-oxidant effects (48). In fact, sensitivity of
many tumor cells to curcumin correlates with generation
of ROS (49) and many well-known antioxidants prevent
curcumin-induced apoptosis (50). At the same time how-
ever, curcumin is a potent scavenger of ROS (51) and
increases the level of glutathione (52,53).
This plethora of curcumin’s effects can be explained by
the pleiotropic activity of curcumin on the one hand, and
by its activity on gene transcription regulation on the
other. Indeed, curcumin inhibits AP-1 transcription
factor, which is involved in apoptotic program and regu-
lation of cell proliferation of many cells (54–56).
Similarly, NF-kB transcription factor, which is involved
in pro-survival and apoptotic pathways, is inhibited by
curcumin (57–60). Recently, curcumin has been shown
to repress histone acetyltransferase-dependent chromatin
transcription by inhibiting its p300/CREB-binding pro-
tein (61). p300 is a ubiquitously expressed global trans-
criptional coactivator that plays critical roles in various
cellular phenomena including cell cycle control, differ-
entiation and apoptosis (62).
Non-Apoptotic Cell Death: Mitotic Catastrophe
Clearly we are far away from completely elucidating the
mechanisms of curcumin-induced cell death. However,
curcumin is an extremely powerful inducer of cancer cell
death and it can overcome resistance to many apoptosis-
inducing factors by activating alternative apoptotic
pathways or another type of cell death, namely mitotic
catastrophe. Accordingly, we showed that curcumin can
overcome the resistance of HL-60 cells with a multiple
drug resistant phenotype (44), as well as the resistance of
calcitriol-differentiated HL-60 cells to DNA-damage-
induced apoptosis by activating other cell signaling
pathways leading to cell death (63). Other studies from
our group also demonstrated that curcumin can over-
come the broad resistance to cell death caused by
expression of Bcr-Abl in mouse cells (64) as well as of
the HL-60-derived HCW-2 cell line that is highly resistant
to apoptosis (65). These cells upon curcumin treatment
undergo mitotic catastrophe, which is terminated by
caspase 3 activation and oligonucleosomal DNA degra-
dation. The term mitotic catastrophe indicates a form
of cell death that is caused by aberrant mitosis. Mitotic
catastrophe is associated with the formation of multi-
nucleate, giant cells that contain uncondensed chromo-
somes, and is morphologically distinct from apoptosis
(66). It seems that the target for curcumin action in
mitotic catastrophe is Survivin, a modulator of cell
division and apoptosis in cancer. It is also postulated
that curcumin can counteract the induction of prosurvi-
val factors by radio/chemoteraphy, thus potentiating
the effect of chemotherapy and inhibiting metastasis
dissemination (54).
Enhancing Cytotoxicity
Concomitantly with these and other data showing that
curcumin enhances the cytotoxicity of chemotherapeutic
agents (57,58,67,68), there are reports that show a
protective effect of curcumin against apoptosis induced
by other factors (52,56,69). Obviously, some discrepancy
can be explained by the pleiotropic activity of curcumin,
which has many molecular targets inside the cell.
However, many of the aforementioned studies, including
ours, are based on the assumption that apoptosis is
characterized (and should be detected) by oligonucleo-
somal DNA degradation. This can be a misleading
concept, since it has been reported that cell death can
occur independently from DNA degradation (70), and
very recently we showed that curcumin can induce cell
death of Jurkat cells despite a simultaneous inhibitory
effect on DFF40/CAD endonuclease activity (71). Thus,
it is possible that discrepancy of data on protection
against cell death by curcumin can be accounted for, at
least in part, by this methodological bias, taking into
account that the symptoms of cell death induced by
curcumin can be different and depend on the cell context.
Proteasome Activation
Another possible explanation for these discrepancies
relies on the capability of curcumin to exert a biphasic
effect, depending on its concentration. As an example of
such a behavior, Ali and Rattan recently reported that
curcumin at different concentrations has a biphasic effect
of proteasome activity in keratinocytes (72). It was
previously reported that curcumin inhibited proteasome
activity (73). In their paper, Ali and Rattan show that
curcumin treatment (up to 1mM for 24h) increased
chymotrypsin-like activity of the proteasome by 46%
compared with that in untreated keratinocytes. However,
higher concentrations of curcumin were inhibitory,
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of its initial value. Taking into account that proteasome
inhibition induces apoptosis, while proteasome activation
promotes cell survival, it is conceivable that a biphasic
behavior of curcumin on proteasome can lead to either
apoptosis or survival, depending on the dose used. The
biphasic effect of curcumin can also impinge on the type
of cell death. In one report curcumin induces apoptotic
changes, including JNK activation, caspase-3 activation,
and cleavage of PARP and PAK2, at concentrations
lower than 25mM in human osteoblast cells, while treat-
ment with 50–200mM does not induce apoptosis, but
rather triggers necrotic cell death (74). While treatment
with 12.5–25mM curcumin directly increased intracellular
oxidative stress, 50–200mM curcumin had far less effect.
Pretreatment of cells with N-acetyl cysteine or alpha-
tocopherol, that are ROS scavengers, attenuated the
intracellular ROS levels increase and converted the
apoptosis to necrosis induced by 12.5–25mM curcumin.
A dose-dependent decrease in intracellular ATP levels
after treatment of osteoblast cells with curcumin was
observed and pre-treatment of cells with antimycin or
2-deoxyglucose to cause ATP depletion significantly
converted 12.5–25mM curcumin-induced apoptosis to
necrosis. This is in agreement also with previously
published data indicating that ATP levels are crucial in
the apoptosis/necrosis switching mechanism (75). It
appears from this study that curcumin dosage treatment
determines the possible effect on ROS generation,
intracellular ATP levels, and cell apoptosis or necrosis
in osteoblast cells. Another example of biphasic activity is
given by the temporal effect of curcumin on NF-kB.
Notarbartolo et al. reported an increase in NF-kB levels
after 8h of treatment and a decrease after 16h (76).
Inhibition of hTERT
Another possible activity of curcumin able to induce cell
death processes is the inhibition of hTERT, the active
subunit of telomerase (77,78). In MCF-7 cells, telomerase
activity decreased with increasing concentrations of
curcumin, inhibiting about 93.4% activity at 100mM
concentration. The inhibition of telomerase activity in
MCF-7 cells may be due to down-regulation of hTERT
expression. Increasing concentrations of curcumin caused
a steady decrease in the level of hTERT mRNA in
MCF-7 cells, whereas the level of hTER and c-myc
mRNAs remained the same. hTERT is activated in
cancer cells and prevents telomere shortening and thus
the activation of apoptotic processes. The inhibition of
hTERT is an additional mechanism by which curcumin
can induce cell death in cancer cells (79).
Among the targets of curcumin there is also the
mammalian target of rapamycin (mTOR), an important
regulator of autophagic cell death (80). At physiological
concentrations (2.5mM), curcumin rapidly inhibits phos-
phorylation of mTOR and its downstream effector
molecules, p70 S6 kinase 1 (S6K1) and eukaryotic
initiation factor 4E (eIF4E) binding protein 1 (4E-BP1),
in a panel of cell lines (Rh1, Rh30, DU145, MCF-7 and
HeLa). Curcumin also inhibits phosphorylation of Akt in
these cells, but only at high concentrations (440mM) (80).
Since mTOR is a pivotal player of autophagy, we
speculate that curcumin may execute its cell death activity
also through the induction of such a mechanism.
Finally, curcumin can induce apoptosis via ER stress in
HL-60 cells (81). On the whole, all the aforementioned
data indicate that curcumin can induce cell death via
different molecular pathways and with different
executing mechanisms, i.e. classical apoptosis, but also
mitotic catastrophe, necrosis and maybe autophagy
(Fig. 1).
Targets for Anti-cancer Drugs
Several next generation anti-cancer drugs are emerging,
among which there are, as examples, monoclonal anti-
bodies that target p53, NF-kB, AKT and Peroxisone
Proliferator-Activated Receptor gamma, and small mole-
cules that inhibit oncogenic tyrosine kinases. Many of
these proteins are also a target for curcumin and other
phytochemicals, and thus advanced multidrug protocols
of cancer treatment could envisage the use of curcumin
as an adjuvant drug to increase treatment efficacy.
Nevertheless, since curcumin has such a wide range of
targets, it is possible, at least in principle, that it can
counteract rather than potentiate the effect of therapy in
some types of cancer. For example, there are reports
that curcumin can inhibit chemotherapeutic effects by
reducing camptothecin-, mechlorethamine- or doxorubi-
cin-induced apoptosis in breast cancer cells (68). These
findings clearly suggest that each possible interaction
between curcumin and other drugs used in therapy must
be examined carefully before clinical use, especially when
treatments of cancer are considered. Indeed, we should
remember that in in vitro experiments curcumin can also
induce cell death in normal cells, such as rat thymocytes
and human T cells (44,82,83).
Curcumin and the Nervous System: A More
Sensitive Target is Neuroprotection
Beside cancer, another condition in which cell death
processes are deeply involved is neurodegeneration. In the
central nervous system of rats, curcumin exerts a pro-
tective effect against neurodegeneration (84,85). Possible
mechanisms of neuroprotection exerted by curcumin
include inhibition of glutamate-mediated excytotoxicity,
antioxidant activity, and induction of chaperone proteins.
Indeed, in cultured neurons, treatment with curcumin
reduced cell demise mediated by glutamate-induced
184 Curcumin, cell death and agingCa(2þ) influx and caspase-3 activation (86). In another
in vivo study, parkinsonian neurotoxin (MPTP)-induced
GSH depletion and lipid peroxidation in rat striatum
and mid-brain was blocked by curcumin treatment (87).
Finally, AD and other neurodegenerative diseases such
as Parkinson’s and Huntington’s disease, amyotrophic
lateral sclerosis and Friedreich’s ataxia, can have define
as pathogenic moment the production of abnormally
aggregated proteins. The pathogenic aggregation of
proteins in non-native conformation is generally asso-
ciated with metabolic derangements and excessive pro-
duction of ROS. The correct folding of the proteins is
carried out by heat-shock proteins, a group of proteins
that are highly conserved through evolution. Curcumin
not only serves as an antioxidant but, in addition, it is
a strong inducer of the heat-shock response (88,89).
Moreover, it is reported that curcumin avoids lipid
peroxidation, lipofuscin and b-amyloid (A-b) accumula-
tion and cognitive impairments in rats (85,90,91).
These animal studies suggest a possible direct protective
action toward AD and represent the rational basis for
Phase II studies on patients with mild-to-moderate AD
(92). The possible use of curcumin as a neuroprotective
drug is of potentially enormous importance; indeed
neurodegenerative diseases such as AD affect millions
of people world-wide and are becoming a dramatic health
emergency in developed countries. Nevertheless, this
curcumin activity at the level of central nervous system
raises a question about its pharmacokinetics. Indeed, the
main limitation of curcumin-based therapies appears at
present to be the low bioavailability of such a drug
outside the gastrointestinal tract. This limitation may be
overcome by different strategies, one of which is the
synthesis of curcumin-related analogs with similar or
even increased pharmacological activity (93–95). These
compounds could be linked to delivery systems that can
focus the drug directly to target cells, thus overcoming
the problem of poor bioavailability of curcumin (95).
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Figure 1. Main molecular targets of curcumin that lead to different types of cell death. Flashes indicate the main biological end points preceding
cell death. DFF40: CAD DNA endonuclease; hTERT: telomerase catalytic subunit; ER: endoplasmic reticulum; mTOR: mammalian Target Of
Rapamycin, Survivin: IAP family member involved in cytoskeleton stability.
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Information indicates that longevity results from the
combination of genetic, environmental and stochastic
components (96). Aging is thought to be a passive
process not genetically determined that results from two
opposite phenomena: a deterioration process occurring at
molecular, cellular and organismal levels due to exposure
to damaging agents on the one hand, and the action of
many enzymatic and non-enzymatic systems that attempt
to counteract such deterioration (remodeling) on the
other. This latter phenomenon can occur to a different
extent of efficacy because of genetic or environmental
parameters. The most efficient is the system that deals
with deteriorative process, the longer living will be the
organism, and the more delayed will be the aging process.
The genetic background of every individual can (still)
not be changed; while it is possible to envisage interven-
tions on the environment that can help in retarding the
aging process.
To this end, the use of phytochemicals such as
curcumin can be considered. Indeed, as mentioned
above, curcumin exerts powerful anti-oxidant and anti-
inflammatory activities that can counteract two phenom-
ena thought to be among the main causes of aging,
i.e. inflammation and oxidative stress. Curcumin can thus
be considered as a possible tool to slow down or delay
senescence as well as the onset or progression of many
age-related diseases. As far as apoptosis, several studies
reveal that cells from aged individuals are more resistant
to apoptosis vis a vis cells from younger subjects (97–99).
In particular this phenomenon has been observed in
peripheral blood mononuclear cells (lymphocytes and
monocytes). A peculiar feature of immunosenescence
(the aging process of the immune system) is indeed the
accumulation of long-living memory cells that are highly
resistant to apoptosis (100,101). Such an accumulation,
together with a decreased output of virgin lymphocytes
from bone marrow leads to a decreased capacity of the
immune system to cope with viral and bacterial infections
and consequently to increased morbility and mortality.
In order to restore, at least partially, immune system
function and delay immunosenescence, many different
strategies have been proposed [for a review see (102)].
One strategy is to avoid the accumulation of long-living
memory lymphocytes. Indeed, these cells, generated
mainly in response to chronic exposure to common
viral antigens such as Epstein–Barr virus and
Cytomegalovirus, are weakly responding cells but do
produce inflammatory cytokines (103–105). Thus, it is
legitimate to predict that their deletion would lead to an
improvement of the immune system in elderly individuals.
Many purging techniques are technically available, even
though they are quite unaffordable from an economic
point of view and, most importantly, they would have
an unpredictable impact on the whole organism (102).
Perhaps, administration of dietary compounds such as
curcumin can protect organisms not only against pro-
liferative pathologies (cancer chemoprevention) as dis-
cussed, but also can maintain the susceptibility to
apoptosis of memory lymphocytes. Thus curcumin can
theoretically contrast the decline of immune function and
eventually the process of aging. Once again this possi-
bility must be experimentally tested, since levels of
curcumin outside the gastrointestinal tract could be
insufficient to induce such an effect.
Conclusions 1: Curcumin as a Pleiotropic
Anti-aging Factor?
Curcumin is an approved food additive that appears to
have substantial beneficial effects as it has anti-oxidant,
anti-inflammatory and anti-proliferative activities. These
activities and the main recognized molecular targets of
curcumin are depicted in Fig. 2. Due to these actions,
curcumin can impinge upon several conditions (repre-
sented as circles in the figures), among which cancer,
neurodegeneration and aging are the most important.
In this review we focused mainly on the effects on
apoptosis and the consequences of such effects in neuro-
degeneration and aging. According to present knowledge,
apoptosis is mainly involved in the first two conditions,
i.e. cancer and neurodegeneration, while aging is likely
more affected by inflammation. Nevertheless, as dis-
cussed in the previous paragraph, it is possible that a
modulation of the susceptibility to apoptosis of immune
cells could impinge upon the aging process. To conclude,
curcumin appears to have positive effects on cancer,
neurodegeneration and possibly aging through its capa-
bility to modulate cell death. It is interesting to note
however that there is, to our knowledge, a lack of data
on animal models regarding the effects of curcumin
administration on animal life span, similar to those
obtained for other phytochemicals such as resveratrol.
These kinds of studies are urgently needed in order to
assess whether curcumin does really impact on aging
and longevity and whether it should be considered as a
possible pharmaceutical tool to delay the aging process.
Conclusions 2: Is the Effect of Curcumin an
Example of Xenohormesis?
Curcumin appears to possess all the desirable features
of a desk-designed, multipurpose drug. Why should a
phytochemical such as curcumin be so effective in human
cells? It is well-known that other xenobiotics exert
beneficial effects in humans, e.g. fungine antibiotics.
Nevertheless in this case, the beneficial effects are largely
independent of the host organism, while in the case of
phytochemicals, these effects are basically due to
186 Curcumin, cell death and agingactivation of host response mechanisms. This is a
completely different strategy to induce protection
toward noxae in an organism, for which we can identify
hormesis (106,107). The term ‘hormesis’ refers to
beneficial actions resulting from the response of an
organism to a low-intensity stressor. Many of the
phytochemicals present in vegetables and fruits may
have evolved as toxins (to dissuade insects and other
predators) that, at subtoxic doses, activate adaptive
cellular stress-response pathways (108). This seems not
to be the case curcumin, which is nontoxic even at high
doses, so a different concept of hormesis should be
considered. As proposed by Sinclair and Howitz, organ-
isms can pick up on chemical stress cues from other
species under stress, either in their food or environment,
and use these to activate their own defense pathways in
preparation for adverse conditions (109–111).
This idea is known as ‘the Xenohormesis Hypothesis’.
According to this hypothesis, curcumin and other phyto-
chemicals could have been selected in plants as upstream
stress signaling molecules able to induce a protective
response toward different types of stresses (UV, drought,
diseases, insect attack, etc.). Phylogenetic studies suggest
that plants and animals largely share the same molecular
pathways in order to respond to stress, so it is conceiv-
able that a molecule produced in plants can be effective
also in animals, and particularly in mammals and
humans as well. Thus, the effect of these phytochemicals
could be present also in organisms different from which
they were derived. Ali and Rattan have recently proposed
that curcumin could be a useful ‘hormetin’ for a series
of different treatments (72). A xenohormetic mechanism
of curcumin would also fit with its very broad range of
effects. The phenomenon of xenohormesis directly comes
from heterotrophy, that is, the dependence for survival
on eating other organisms. In this case heterotrophy
would concern not only caloric intake and micronutri-
ents, but also the intake of such molecules with
pharmacological activities. Eat something to acquire its
own qualities is an ancestral idea of mankind. Curcumin
demonstrates the advantage of such an idea and
xenohormesis can explain why.
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